rais gilead fve biktarvi filgotinib
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jul
estim jul
price data jul
rate updat jul
currenc amount express
methodolog valu compani
gilead report strong second-quart result ahead
estim launch hiv combin regimen
biktarvi drive perform gilead increas
guidanc product sale
billion larg biktarvi strength estim
low end prior guidanc billion
significantli rais fair valu estim
account rapid shift biktarvi older
hiv medicin well grow confid
potenti filgotinib rheumatoid arthriti gilead
increasingli face gener version oldest hiv
medicin next year think signific
improv newer version well extens
new area like oncolog immunolog support
stabl wide moat share appear incorpor overli
pessimist long-term evolut firm pipelin
highlight hiv filgotinib gilead biggest growth
opportun biktarvi continu beat estim
gilead rapidli gain switch older hiv
medicin competitor like glaxo
increas biktarvi estim remain somewhat
cautiou long-term threat new two-drug
regimen like glaxo dovato approv
 april list price biktarvi
highlight opportun hiv drug descovi pre-
exposur prophylaxi prep approv
indic expect fourth quarter drug
abl show efficaci benefit gilead older drug
truvada see prep sale today roughli billion
annual stronger safeti profil recent data
descoy potenc like enough gilead push
patient convert descovi despit truvada gener
potenti long-act inject hiv regimen
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
develop market therapi treat life-threaten
infecti diseas core portfolio focus hiv
hepat acquisit coru pharma myogen cv
therapeut arresto bioscienc calistoga broaden focu
includ pulmonari cardiovascular diseas cancer gilead
acquisit pharmasset brought right hepat drug sovaldi
also part combin drug harvoni kite acquisit boost
gilead exposur cell therapi oncolog
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
minim impact although greater catastroph phase
coverag respons could weigh firm
uncertain gilead could potent capsid inhibitor
use regimen combin dose
interv still determin
gilead biggest recent news confirm firm
plan file approv filgotinib rheumatoid arthriti
 europ base encourag
discuss fda multipl posit phase
readout increas sale forecast potenti
billion peak probabl approv
addit think gilead decis expand
collabor galapago make good strateg sens
gilead gain access galapago research platform
therapi clinic trial right outsid europ
expand gilead inflamm pipelin includ
phase idiopath pulmonari fibrosi
phase osteoarthr give firm
base european research expand galapago
deal cost billion up-front payment
billion equiti invest make much
dent gilead cash balanc stood billion
end second quarter deal close third
quarter expect deal inflamm
oncolog area addit gilead recent hire
christi shaw head kite cell therapi divis
experi lilli novarti allow gilead form
clearer vision oncolog strategi come
month although wari yescarta long-term sale
potenti crowd lymphoma market
gilead exposur potenti drug price reform
 think firm particularli expos
medicar part reform discuss rebat rule
dead suppli chain benefit drug firm pressur
gilead high exposur part
estim total sale firm disclos
sale part howev gilead reli larg
price increas sale growth inflat cap could
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
